Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Expenses (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Operating Expenses for 7 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 16.8% to $22.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.8 million, a 16.81% decrease, with the full-year FY2025 number at $84.8 million, down 16.81% from a year prior.
  • Operating Expenses was $22.7 million for Q4 2025 at Fulcrum Therapeutics, up from $21.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $36.1 million in Q2 2022 to a low of $19.4 million in Q4 2024.
  • A 5-year average of $26.0 million and a median of $26.6 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 50.09% in 2022, then plummeted 32.69% in 2024.
  • Fulcrum Therapeutics' Operating Expenses stood at $28.6 million in 2021, then rose by 0.14% to $28.7 million in 2022, then rose by 0.72% to $28.9 million in 2023, then plummeted by 32.69% to $19.4 million in 2024, then grew by 16.8% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Operating Expenses are $22.7 million (Q4 2025), $21.9 million (Q3 2025), and $19.8 million (Q2 2025).